Quanterix Corporation
5.17-0.31 (-5.66%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · QTRX · USD
Key Stats
Market Cap
240.23MP/E (TTM)
-Basic EPS (TTM)
-1.81Dividend Yield
0%Recent Filings
8-K
Annual meeting adjourned for votes
Quanterix Corporation convened its 2025 Annual Meeting on September 23 but adjourned it without business to give stockholders more time to vote on key proposals, reconvening September 29. Proposals 5 and 6, aiming to eliminate supermajority voting requirements for charter and bylaw amendments, need 75% approval; 99% of voted shares support them, but that's just 74.8% of outstanding stock. The board urges voting; proxies stand unless revoked. Failure risks further adjournment.
10-Q
Q2 FY2025 results
Quanterix's Q2 FY2025 revenue fell 29% y/y to $24.5M, driven by a 15% drop in product sales to $16.8M from softer academic and pharma demand amid funding cuts and economic pressures, while service revenue plunged 48% y/y to $7.1M after key collaborations ended. Gross margin contracted to 46.2% from 64.7%, reflecting higher inventory reserves and lower production volumes, yet operating cash burn eased to $19.5M YTD from $25.1M. The Emission acquisition closed in January 2025 for $9.0M cash plus $6.6M contingent consideration (now $2.7M), adding $12.9M in developed technology amortized over 14 years, though full $6.4M goodwill was impaired due to macro headwinds. Cash swelled to $261.2M, bolstered by $94.6M in marketable securities sales, with no debt but $35.5M in lease liabilities. Akoya merger followed in July for 7.8M shares and $101.7M cash, eyeing synergies. Restructuring trimmed $85M annualized costs. Competition from analog immunoassay rivals lingers.
8-K
Q2 revenue drops, Akoya integration advances
Quanterix reported Q2 2025 revenue of $24.5 million, down 29% from $34.4 million last year, amid US academic market weakness, yet Alzheimer's diagnostics revenues tripled year-over-year. The company completed its Akoya Biosciences acquisition in early July, integrating blood and tissue biomarker platforms, and captured 75% of its $85 million synergy target through cost cuts. It projects full-year revenue of $130-135 million and cash flow breakeven in 2026. Integration risks could delay synergies.
8-K
Quanterix-Kent Lake board pact
Quanterix inked a cooperation pact with Kent Lake, its 4.4% stakeholder, on August 4, 2025, to add a new independent director by December 1 via joint search, while withdrawing Kent Lake's nomination notices and proposals. The company will push for board declassification at the 2025 annual meeting and switch to majority voting in uncontested elections. Kent Lake commits to standstill and board-aligned voting until 2027. Deal averts proxy fight, sharpening focus on strategy.
8-K
Quanterix launches cost cuts
Quanterix Corporation committed to a cost-cutting plan on July 18, 2025, terminating staff to integrate its Akoya Biosciences acquisition and unlock synergies. The move targets $18.0 million in annual cash savings through headcount reductions, mostly done by Q3 2025, but carries $2.5 million in severance costs this year. Disruptions could hinder operations.
BDX
Becton, Dickinson and Company
181.52-2.69
BIO
Bio-Rad Laboratories, Inc.
319.47-10.95
BRKR
Bruker Corporation
37.74-0.98
DGX
Quest Diagnostics Incorporated
174.78-3.50
DHR
Danaher Corporation
214.01-2.89
IQV
IQVIA Holdings, Inc.
217.83-0.30
IRIX
IRIDEX Corporation
1.03+0.02
LAB
Standard BioTools Inc.
1.19-0.08
QDEL
QuidelOrtho Corporation
27.94-0.25
QSI
Quantum-Si Incorporated
2.14-0.04